Mindbio awaits phase 2B trial results for MB22001

Executive Summary

• Mindbio Therapeutics is nearing the completion of its Phase 2B trial for its lead candidate, MB22001, a microdose formulation of LSD for major depressive disorder, with top-line data expected in the fourth quarter.
• The company has established a new subsidiary, Mindbio Therapeutics Labs Pty. Ltd., to explore R&D opportunities in Australasia, funded by $100,000 in convertible loans from Shape Capital and CEO Justin Hanka.
• The board approved the issuance of 61.5 million restricted stock units (RSUs) to directors, officers, and employees in lieu of cash compensation.

Key Details

• Clinical Trial Status:
  • MB22001 is in the completion stages of a Phase 2B trial for major depressive disorder.
  • The trial is a randomized, active placebo-controlled study involving 90 patients.
  • Initial top-line readout of clinical trial data is expected in the fourth quarter.
  • Results will determine advancement into Phase 3 trials and potential commercialization.
• Drug Profile & Previous Data:
  • MB22001 is a proprietary, titratable microdose formulation of lysergic acid diethylamide (LSD) designed for safe, at-home patient use.
  • It is non-hallucinogenic.
  • Previous trials (MB2001) showed statistically significant improvements in mood and sleep (quality, total time, REM sleep).
  • Observed a 72% reduction in depressive symptoms sustained six months after an eight-week treatment, measured by the Montgomery Asberg depression rating scale.
  • Patients reported being happier, more energetic, socially connected, creative, less depressed, angry, anxious, and irritable.
• Corporate Restructuring & Financing:
  • Incorporated new subsidiary: Mindbio Therapeutics Labs Pty. Ltd.
  • Purpose: Explore new R&D opportunities in Australasia.
  • Funding: $100,000 committed via two convertible loans.
  • Lenders: Shape Capital Pty. Ltd. and Mindbio CEO/director Justin Hanka.
  • Conversion Terms: Loans convert to an aggregate of 20% equity in the subsidiary.
• Equity Compensation:
  • Board approved issuance of 61.5 million restricted stock units (RSUs) under the omnibus incentive plan.
  • 24 million RSUs issued to four directors, officers, and insiders in lieu of cash compensation.
  • 37.5 million RSUs approved for issue to 11 employees and consultants in lieu of cash compensation.

Notable Quotes

• "We are very pleased to be advancing our work towards completion of phase 2B trials, and we are looking forward to reporting the results later in the year." — Mr. Justin Hanka, CEO